A citation-based method for searching scientific literature

Matthew J Fell, David L McKinzie, James A Monn, Kjell A Svensson. Neuropharmacology 2012
Times Cited: 72







List of co-cited articles
786 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova,[...]. Nat Med 2007
787
54


Metabotropic glutamate receptors: physiology, pharmacology, and disease.
Colleen M Niswender, P Jeffrey Conn. Annu Rev Pharmacol Toxicol 2010
27

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
Bruce J Kinon, Lu Zhang, Brian A Millen, Olawale O Osuntokun, Judy E Williams, Sara Kollack-Walker, Kimberley Jackson, Ludmila Kryzhanovskaya, Natalia Jarkova. J Clin Psychopharmacol 2011
176
27


Identification of a serotonin/glutamate receptor complex implicated in psychosis.
Javier González-Maeso, Rosalind L Ang, Tony Yuen, Pokman Chan, Noelia V Weisstaub, Juan F López-Giménez, Mingming Zhou, Yuuya Okawa, Luis F Callado, Graeme Milligan,[...]. Nature 2008
563
25


Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.
P Jeffrey Conn, Craig W Lindsley, Carrie K Jones. Trends Pharmacol Sci 2009
267
22


Metabotropic glutamate receptors: from the workbench to the bedside.
F Nicoletti, J Bockaert, G L Collingridge, P J Conn, F Ferraguti, D D Schoepp, J T Wroblewski, J P Pin. Neuropharmacology 2011
417
19


Metabotropic glutamate receptors as novel targets for anxiety and stress disorders.
Chad J Swanson, Mark Bures, Michael P Johnson, Anni-Maija Linden, James A Monn, Darryle D Schoepp. Nat Rev Drug Discov 2005
464
18

Metabotropic glutamate receptors as therapeutic targets for schizophrenia.
Paige N Vinson, P Jeffrey Conn. Neuropharmacology 2012
69
18





Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice.
Ruggero Galici, Carrie K Jones, Kamondanai Hemstapat, Yi Nong, Nicholas G Echemendia, Lilly C Williams, Tomas de Paulis, P Jeffrey Conn. J Pharmacol Exp Ther 2006
129
15

Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder.
Eduardo Dunayevich, Janelle Erickson, Louise Levine, Ronald Landbloom, Darryle D Schoepp, Gary D Tollefson. Neuropsychopharmacology 2008
147
15

Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia.
Michael F Egan, Richard E Straub, Terry E Goldberg, Imtiaz Yakub, Joseph H Callicott, Ahmad R Hariri, Venkata S Mattay, Alessandro Bertolino, Thomas M Hyde, Cynthia Shannon-Weickert,[...]. Proc Natl Acad Sci U S A 2004
297
15

Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: Implication in emotional responses and central disinhibition.
Guibao Gu, Daniel S Lorrain, Hongbing Wei, Rebecca L Cole, Xin Zhang, Lorrie P Daggett, Herve J Schaffhauser, Linda J Bristow, Sandra M Lechner. Brain Res 2008
76
13




Pharmacological agents acting at subtypes of metabotropic glutamate receptors.
D D Schoepp, D E Jane, J A Monn. Neuropharmacology 1999
878
12



Pharmacology and functions of metabotropic glutamate receptors.
P J Conn, J P Pin. Annu Rev Pharmacol Toxicol 1997
12

Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action?
Subroto Ghose, Kelly A Gleason, Bryan W Potts, Kelly Lewis-Amezcua, Carol A Tamminga. Am J Psychiatry 2009
74
12


HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity.
Mitsumasa Kurita, Terrell Holloway, Aintzane García-Bea, Alexey Kozlenkov, Allyson K Friedman, José L Moreno, Mitra Heshmati, Sam A Golden, Pamela J Kennedy, Nagahide Takahashi,[...]. Nat Neurosci 2012
177
12

Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent.
Guy A Higgins, Theresa M Ballard, James N C Kew, J Grayson Richards, John A Kemp, Geo Adam, Thomas Woltering, Shigetada Nakanishi, Vincent Mutel. Neuropharmacology 2004
132
12

Prenatal stress induces schizophrenia-like alterations of serotonin 2A and metabotropic glutamate 2 receptors in the adult offspring: role of maternal immune system.
Terrell Holloway, José L Moreno, Adrienne Umali, Vinayak Rayannavar, Georgia E Hodes, Scott J Russo, Javier González-Maeso. J Neurosci 2013
86
12

Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.
Virginia L Stauffer, Brian A Millen, Scott Andersen, Bruce J Kinon, Lisa Lagrandeur, J P Lindenmayer, Juan Carlos Gomez. Schizophr Res 2013
76
12

LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress.
Darryle D Schoepp, Rebecca A Wright, Louise R Levine, Brenda Gaydos, William Z Potter. Stress 2003
173
11

Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s).
Michael P Johnson, David Barda, Thomas C Britton, Renee Emkey, William J Hornback, G Erik Jagdmann, David L McKinzie, Eric S Nisenbaum, Joseph P Tizzano, Darryle D Schoepp. Psychopharmacology (Berl) 2005
126
11

Ionotropic and metabotropic glutamate receptor structure and pharmacology.
James N C Kew, John A Kemp. Psychopharmacology (Berl) 2005
475
11

Recent advances in the phencyclidine model of schizophrenia.
D C Javitt, S R Zukin. Am J Psychiatry 1991
11

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.
Stefan Leucht, Caroline Corves, Dieter Arbter, Rolf R Engel, Chunbo Li, John M Davis. Lancet 2009
11


Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice.
Francesco Matrisciano, Patricia Tueting, Stefania Maccari, Ferdinando Nicoletti, Alessandro Guidotti. Neuropsychopharmacology 2012
86
11

Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.
Chantal Schlumberger, Daniela Schäfer, Caroline Barberi, Lorenzo Morè, Jens Nagel, Małgorzata Pietraszek, Werner J Schmidt, Wojciech Danysz. Behav Pharmacol 2009
68
11

CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [³H]LY459477 autoradiography.
Rebecca A Wright, Bryan G Johnson, Ce Zhang, Craig Salhoff, Ann E Kingston, David O Calligaro, James A Monn, Darryle D Schoepp, Gerard J Marek. Neuropharmacology 2013
67
11

Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.
G J Marek, R A Wright, D D Schoepp, J A Monn, G K Aghajanian. J Pharmacol Exp Ther 2000
227
11



Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans.
Christian Grillon, Jeremy Cordova, Louise R Levine, Charles A Morgan. Psychopharmacology (Berl) 2003
158
9

Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
Linda M Rorick-Kehn, Bryan G Johnson, Jennifer L Burkey, Rebecca A Wright, David O Calligaro, Gerard J Marek, Eric S Nisenbaum, John T Catlow, Ann E Kingston, Deborah D Giera,[...]. J Pharmacol Exp Ther 2007
80
9

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.
Linda M Rorick-Kehn, Bryan G Johnson, Karen M Knitowski, Craig R Salhoff, Jeffrey M Witkin, Kenneth W Perry, Kelly I Griffey, Joseph P Tizzano, James A Monn, David L McKinzie,[...]. Psychopharmacology (Berl) 2007
129
9

Targeting glutamate synapses in schizophrenia.
Julie R Field, Adam G Walker, P Jeffrey Conn. Trends Mol Med 2011
75
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.